224 related articles for article (PubMed ID: 34125296)
21. Effects of quality indicator monitoring for glucocorticoid-induced osteoporosis and trends of drug treatment in a Japanese hospital.
Suda M; Suyama Y; Ohde S; Tsuda T; Sawada H; Kishimoto M; Okada M
Int J Rheum Dis; 2018 May; 21(5):975-981. PubMed ID: 29878618
[TBL] [Abstract][Full Text] [Related]
22. Vitamin D and bisphosphonate therapy in systemic lupus erythematosus patients who receive glucocorticoids: are we offering the best care?
Sapkota S; Baig S; Hess T; O'Connell AM; Menk J; Shyne M; Fazeli P; Ensrud K; Shmagel A
Lupus; 2020 Mar; 29(3):263-272. PubMed ID: 31996109
[TBL] [Abstract][Full Text] [Related]
23. The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis.
Tanaka Y; Soen S; Hirata S; Okada Y; Fujiwara S; Tanaka I; Kitajima Y; Kubota T; Ebina K; Takashi Y; Inoue R; Yamauchi M; Okubo N; Ueno M; Ohata Y; Ito N; Ozono K; Nakayama H; Terauchi M; Tanaka S; Fukumoto S
J Bone Miner Metab; 2024 Mar; 42(2):143-154. PubMed ID: 38538869
[TBL] [Abstract][Full Text] [Related]
24. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions.
Bultink IE; Baden M; Lems WF
Expert Opin Pharmacother; 2013 Feb; 14(2):185-97. PubMed ID: 23317448
[TBL] [Abstract][Full Text] [Related]
25. [Secondary osteoporosis UPDATE. Clinical significance of glucocorticoid-induced osteoporosis].
Suzuki Y; Sato S
Clin Calcium; 2010 May; 20(5):645-53. PubMed ID: 20445275
[TBL] [Abstract][Full Text] [Related]
26. Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice.
Solomon DH; Katz JN; Jacobs JP; La Tourette AM; Coblyn J
Arthritis Rheum; 2002 Dec; 46(12):3136-42. PubMed ID: 12483716
[TBL] [Abstract][Full Text] [Related]
27. Are glucocorticoid-induced osteoporosis recommendations sufficient to determine antiosteoporotic treatment for patients with rheumatoid arthritis?
Lee JH; Cho SK; Han M; Kim D; Bae SC; Sung YK
Korean J Intern Med; 2014 Jul; 29(4):509-15. PubMed ID: 25045299
[TBL] [Abstract][Full Text] [Related]
28. [Glucocorticoid and Bone. Efficacy and safety of bisphosphonate in treatment of glucocorticoid induced osteoporosis].
Tanaka I
Clin Calcium; 2014 Sep; 24(9):1371-8. PubMed ID: 25177010
[TBL] [Abstract][Full Text] [Related]
29. [Vitamin K2 as a potential therapeutic agent for glucocorticoid-induced osteoporosis].
Tanana I; Oshima H
Clin Calcium; 2006 Nov; 16(11):1851-7. PubMed ID: 17079852
[TBL] [Abstract][Full Text] [Related]
30. Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis.
Chiodini I; Falchetti A; Merlotti D; Eller Vainicher C; Gennari L
Expert Rev Endocrinol Metab; 2020 Jul; 15(4):283-298. PubMed ID: 32584619
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study.
Tanaka I; Tanaka Y; Soen S; Oshima H
J Bone Miner Metab; 2021 May; 39(3):446-455. PubMed ID: 33211212
[TBL] [Abstract][Full Text] [Related]
32. Use of bisphosphonates and dual-energy X-ray absorptiometry scans in the prevention and treatment of glucocorticoid-induced osteoporosis in rheumatology.
Wall E; Walker-Bone K
QJM; 2008 Apr; 101(4):317-23. PubMed ID: 18270228
[TBL] [Abstract][Full Text] [Related]
33. [Secondary osteoporosis. Evidence of treatment efficacy in patients with glucocorticoid-induced osteoporosis].
Sato S
Clin Calcium; 2007 Apr; 17(4):600-5. PubMed ID: 17404491
[TBL] [Abstract][Full Text] [Related]
34. The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study.
Majumdar SR; Lix LM; Morin SN; Yogendran M; Metge CJ; Leslie WD
J Rheumatol; 2013 Oct; 40(10):1736-41. PubMed ID: 23818715
[TBL] [Abstract][Full Text] [Related]
35. Increase in prophylaxis of glucocorticoid-induced osteoporosis by pharmacist feedback: a randomised controlled trial.
Klop C; de Vries F; Vinks T; Kooij MJ; van Staa TP; Bijlsma JW; Egberts AC; Bouvy ML
Osteoporos Int; 2014 Jan; 25(1):385-92. PubMed ID: 24221450
[TBL] [Abstract][Full Text] [Related]
36. [Guidelines for the treatment of glucocorticoid-induced osteoporosis and their future problems].
Soen S
Clin Calcium; 2006 Nov; 16(11):1788-96. PubMed ID: 17079844
[TBL] [Abstract][Full Text] [Related]
37. Treatment options for glucocorticoid-induced osteoporosis.
Chiodini I; Merlotti D; Falchetti A; Gennari L
Expert Opin Pharmacother; 2020 Apr; 21(6):721-732. PubMed ID: 32004105
[TBL] [Abstract][Full Text] [Related]
38. [Glucocorticoid and Bone. Updated Japanese guidelines for the management of glucocorticoid-induced osteoporosis].
Suzuki Y
Clin Calcium; 2014 Sep; 24(9):1309-18. PubMed ID: 25177003
[TBL] [Abstract][Full Text] [Related]
39. Glucocorticoid-induced Osteoporosis.
Whittier X; Saag KG
Rheum Dis Clin North Am; 2016 Feb; 42(1):177-89, x. PubMed ID: 26611558
[TBL] [Abstract][Full Text] [Related]
40. Bone safety of low-dose glucocorticoids in rheumatic diseases.
Saag KG
Ann N Y Acad Sci; 2014 May; 1318():55-64. PubMed ID: 24815076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
